Abstract: This invention relates to complexes of certain divalent and polyvalent d-orbital metals of first transition series of the Periodic Table of Elements, from Group IV to Group VI, and including molybdenum, having a hydroxy acid [HA] and an amino acid [AA] moiety concurrently bound to a single said metal and having a spirocyclic, bidentate chelate structure of formula (I). Upon topical application said metal complexes undergo enhanced skin penetration without causing skin irritation.

Abstract: The present invention relates to medical use of liposomes, more particular the first medical use of sPLA2 hydrolysable liposomes. Such liposomes may be used for targeted delivery of therapeutic agents to cancerous tissue and in such embodiments; the therapeutic agents are typically small molecule antitumor agents. Other aspects of the inventions relates to methods of reducing the side effects of therapeutic agents, e.g. reducing nephrotoxicity, neurotoxicity and gastrointestinal toxicity of a therapeutic agent. Yet another aspect of the present invention relate to methods of prolonging the therapeutic effect of a therapeutic agent.

Abstract: Formulations and methods are disclosed which are effective to kill or control bacteria in the nares including gram-positive bacteria strains of S. aureus that are antibiotic resistant (MRSA—methicillin-resistant Staphylococcus aureus. A preferred composition comprises one or more medium-chain alcohols (dodecanol), glycerol monoesters (glycerol monocaprylate or glycerol monolaurate), and/or benzoic acid or benzoic acid analog, in a suitable pharmaceutical carrier, preferably an ointment, along with an odorant compound, preferably eucalyptus oil. The formulations and variations of the formulation may also be used on open wounds or lesions as well as intact skin.

Abstract: This invention relates to a bipolar antimicrobial particle for use in laundry detergent compositions, fabric conditioners, personal care and cosmetic compositions and a process for making the same. In view of the foregoing, it is an object of the present invention to provide a stabile antimicrobial agent immobilised on a carrier particle. It is a further objective to provide an antimicrobial particle with improved retention to the fabric so that larger amounts of antimicrobial will be available even after rinsing. Surprisingly it has been found that antimicrobial molecules tagged by surface reaction onto naturally occurring asymmetric clay surfaces, act as an antimicrobial particle with improved retention properties with improved stability.

Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.

Abstract: A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.

Abstract: A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.

Abstract: According to one embodiment, a coagulant comprising calcium nitrate and an antimicrobial agent is disclosed. The coagulant may be used in the molding process to releasably bond the substrate material to the mold and to bond to the antimicrobial to the substrate material.

Abstract: The invention provides a method of treatment of cancer, wherein a individual doses of picoplatin, each of less than about 200 mg picoplatin content, the individual doses having high oral bioavailability, are administered to a patient in need thereof. The oral bioavailability can be greater than about 50%, or greater than about 75%, or greater than about 90%, depending upon the particular dosage form and dosing regimen used. The invention provides a quasi-metronomic dosing schedule including drug dosing intervals and drug intermission intervals, optionally including fasting periods prior to and following administration of each individual dose of picoplatin.

Abstract: A synergistic antimicrobial composition containing 3-iodo-2-propynyl-butylcarbamate and fluometuron.

Abstract: Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.

Abstract: Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides a method of treatment of metastatic hormone-refractory prostate cancer involving substantially as concurrent administration of picoplatin and docetaxel. Prednisone may also be administered. Dosages and dosing regimens are provided.

Abstract: A synergistic antimicrobial composition containing flumetsulam or diclosulam; and zinc pyrithione.

Abstract: A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.

Abstract: Supramolecular complexes that target and cleave DNA are provided. The supramolecular complexes include at least one metal-to-ligand charge transfer (MLCT) light absorbing unit, at least one Pt based DNA binding unit, and at least one bridging unit that serves to connect the components. The Pt-based DNA binding unit binds the complex to DNA, and the MLCT unit absorbs light, thereby sensitizing molecular oxygen to produce reactive oxygen species in close proximity to the complex and the bound DNA. The reactive oxygen species cleave the bound DNA.

Abstract: Modified green tea polyphenols and methods of their use are provided. One aspect provides compounds and compositions containing green tea polyphenols with one on more ester-linked fatty acids.

Abstract: The present invention relates to a compound of formula (I). Provided is also a method of killing a cell that comprises administering the compound of formula (I). Provided is also a method of treating cancer or diabetes in a mammal that comprises administering the compound of formula I and respective pharmaceutical compositions thereof.

Abstract: A shampoo composition is described which includes from 1 to 25% by weight of mild surfactants, from 0.001 to 5% by weight of citrus fibers, from 0.01 to 5% by weight of anti-dandruff zinc salts, and a cosmetically acceptable carrier. The citrus fibers help structure the composition to maintain phase stability, provide appropriate viscosity and achieve deposition of the anti-dandruff zinc salts.

Abstract: The invention includes a microbe-mitigating architectural barrier that includes a barrier forming material, and at least one biocide. The barrier forming material may be a bitumen product, an elastomeric polymer and combinations thereof. The microbe-mitigating architectural barrier may be formed by applying an emulsion composition directly to an architectural surface, or it may be preformed and adhered or otherwise secured to the architectural surface in the form of a sheet or film. The invention also includes architectural assemblies and/or building envelopes that include the microbe-mitigating barrier. Related methods are encompassed within the scope of the invention.

Abstract: Method for determining whether a mammalian subject having a cancer belongs to a first or a second group, wherein subjects of the first group are more likely to respond to a platinum-based therapy than subjects of the second group, comprising the steps of: evaluating the amount of RBM3 protein or RBM3 mRNA present in at least part of a sample earlier obtained from said subject, and determining a sample value corresponding to said amount; comparing the sample value with a reference value; and, if said sample value is higher than said reference value, concluding that said subject belongs to a first group; and if said sample value is lower than or equal to said reference value, concluding that said subject belongs to a second group. There is further provided means useful in the establishment of a treatment prediction.

Abstract: The present invention relates to an aqueous hair cleansing agent which includes the following components (A), (B): (A) sulfate-type anionic surfactant having a specific structure, (B) polyoxyethylene alkyl ether-type nonionic surfactant having a specific structure, and water, wherein ratio of weight represented by (B)/((A)+(B)) is 1% to 25%.

Abstract: This invention is based on the observed oxidative stress and increased risk on cardiovascular diseases in subjects with increased lipid peroxidation, in particular with women using oral contraceptives and in hormone replacement therapies. The invention provides compositions and combinations, particularly useful in preventing and or reducing the increased lipid peroxidation in subjects in need thereof. These compositions are based on the synergistic combination of zinc and/or a hydroxyl radical scavenger in reducing lipid peroxidation.

Abstract: An improved method, formulation and kit for the treatment of acne vulgaris are disclosed. The formulation is effective in inhibiting or killing the Proprionibacterium microorganism without utilizing antibiotics A preferred formulation alleviates the four pathogenic factors involved in the development of acne a) the putative pathogen of acne, Proprionibacterium acnes, b) abnormal desquamation of sebaceous-follicle epithelium (comedogenesis), c) the androgen-induced excessive sebum production, and d) the follicular reactivity (inflammation). The formulations are preferably applied as a cream, lotion or an emulsion.

Abstract: An herbicidal composition containing (a) florasulam and (b) at least one preemergent annual grass herbicide selected from the group consisting of dithiopyr and pendimethalin provides synergistic control of selected weeds in turf.

Abstract: A treatment system and method for osteopenia and osteoporosis using non-synthetic bio-available hormones, vitamins, minerals, and agents may be customized by varying the dosage and formulation of the components to maximize therapeutic effect, bioavailability, and patient comfort and compliance with their treatment method, the treatment system including a storage unit including a determined number of applications of hormones, minerals, and vitamins of appropriate dosages for treating the patient with osteopenia and osteoporosis.

Abstract: To provide a cosmetic composition and a hair wash which are excellent in metal pyrithione salt persistence after washing with a washing liquid containing a surfactant, etc. A cosmetic composition and a hair wash, which comprise a copolymer and a metal pyrithione salt, wherein the copolymer contains constituting units corresponding to a cationic vinyl monomer of a specific structure and constituting units corresponding to a nonionic vinyl monomer of a specific structure.

Abstract: In one aspect, the invention relates to a method for identifying a drug candidate with activity as a neuroprotective agent. The method includes determining whether a compound reduces ATF4 activity; and identifying the compound that reduces ATF4 activity as a drug candidate.

Abstract: Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.

Abstract: A production method is provided for the preparation of small polymer microcapsules with an oil core and solid microspheres, containing high amounts of biocide by internal phase separation from emulsion droplets with ethyl acetate as a solvent. The size of the microcapsules and microspheres can be controlled with a high degree of accuracy between 0.2-20 micrometers in diameter. The microparticles are particularly well suited for coatings such as paints, lacquers and wood preservatives which are to be protected against microorganisms using biocides, as well as for surface protection directly, i.e. without combining the microparticles with a coating material.

Abstract: A method for preparation pharmaceutical compounds in large quantities consists of copper (I) halide, preferably the chloride complex of nicotinic acid characterized by elemental analysis, spectroscopy and crystallographic methods, used for treatment of muscular dystrophy, myopathy, myasthenia gravis, parkinsonism, Chronic Fatigue Syndrome, Male Infertility and post stroke muscle weakness. Chlorobis (nicotinic acid) copper (I) monohydrate complex, its composition [CuCl (nicotinic acid)2]. H2O, has been prepared and its physical and chemical properties as well as its crystal structure have been investigated for the first time.

Abstract: A method for treating a lymphoma selected from non-Hodgkin's and Hodgkin's lymphoma comprising administering an organoarsenic compound having a structure of the formula (I) wherein X is S or Se and R1 and R2 are independently C1-30alkyl(R3, R3?, R4, R5, W and “n” are as defined in claim 1) in particular where the compound is S-dimethylarsinoglutathione, N-(2-S-dimethylarsinothiopropionyl)glycine, 2-amino-3-(dimethylarsino)thio-3-methylbutanoic acid, S-dimethylarsino-thiosuccinic acid or S-dipropylarsino-1-thioglycerol.

Abstract: The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.

Abstract: We disclose a colorless composition comprising metal particles (e.g., silver nanoparticles) and water, wherein said particles comprise an interior of elemental metal (e.g., silver) and an exterior of metal oxide (e.g., one or more silver oxide(s)), wherein the metal nanoparticles are present in the water at a level of about 5-40 ppm, and wherein the composition manifests significant antimicrobial properties. Methods of use of the composition are described. The composition can be incorporated into a hydrogel with essentially no loss of antimicrobial properties. Various metal-containing compositions with unexpected biological efficacy are also disclosed.

Abstract: The present invention relates to combinations of a phenylpyrrole, or a salt thereof, and a pyrion compound which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of a phenylpyrrole selected from fludioxonil, fenpiclonil or pyrrolnitrin, or a salt thereof, together with a pyrion compound selected from 1-hydroxy-2-pyridinone, ciclopirox, ciclopirox olamine, piroctone, piroctone olamine, rilopirox, pyrion disulfide, sodium pyrithione and zinc pyrithione; in respective proportions to provide a synergistic biocidal effect. Compositions comprising these combinations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, engineering material, biodegradable material and textiles against deterioration due to the action of microorganisms such as bacteria, fungi, yeasts, algae, virusses, and the like.

Abstract: The present disclosure provides a drug delivery device comprising a housing defining an airway, wherein the airway comprises at least one air inlet and a mouthpiece having at least one air outlet, at least one heated metal substrate disposed within the airway, at least one drug disposed on the at least one heated metal substrate. Drugs that can be complexed with metals or metal salts and could be deposited as thin films on heated metal substrate for generating thermal condensation aerosols are particularly suited. The metal substrate could be electrically or chemically heated. Further, the chemically heated metal source could be activated by an igniter that generates heat or spark.

Abstract: The instant invention describes methods of treating KCNQ related diseases and disorders using organozinc compounds. In certain embodiments, pain is treated using Zinc Pyrithione.

Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.

Abstract: The present invention relates to sequence selective compounds for targeting therapeutic or diagnostic groups to polynucleotides. More particularly, the present invention relates to sequence selective targeting of metallocomplexes, such as metallodrugs and metallodiagnostics, to polynucleotides.

Abstract: Disclosed herein are compositions and methods for the treatment and/or prevention of pathological conditions associated with ischemia/reperfusion injury and/or hypoxic injury of myocardial cell or tissue.

Abstract: The present invention relates to personal care compositions, especially those shave preparation article and skin care articles which are in the form of a porous dissolvable solid substrate having a surface resident coating comprising at least one skin treatment active. The present invention can deliver a consumer benefit as well as allow for separation of any incompatible actives in the substrate versus the coating.

Abstract: A personal care composition which is preferably a post-foaming gel, said composition comprising an anti-irritation agent; a water dispersible surface active agent, of a carrier comprising water; and optionally a lubricant.

Abstract: The present invention relates to dispersions comprising a biocide selected from tralopyril, zinc pyrithione or tolylfluanid, or a combination of thereof, a polymeric surfactant, an anti-settling agent and one or more carrier liquids. These dispersions have a solids level up to 80% by weight and provide a zero-dust delivery system when used in antifouling coating formulations.

Abstract: A radioactive protection micronutrient formulation system is provided and the system comprises: a formulation consisting essentially of antioxidants, the antioxidants are selected from the group consisting essentially of vitamin C, vitamin E, N-acetyl cysteine, natural mixed carotenoids, and alpha-lipoic acid, vitamin A (palmitate), vitamin D-3 (cholecalciferol), thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid, D-Biotin, selenium (1-seleno-methionine), chromium picolinate, zinc glycinate, calcium citrate and magnesium citrate and mixtures thereof; and plus a booster formulation selected from a group consisting essentially of vitamin C, d-alpha tocopheryl acid succinate, alpha tocopherol, N-acetyl cysteine, natural mixed carotenoids and alpha lipoic acid, the formulation is designed to reduce the risk in humans exposed to doses of ionizing radiation of becoming subjected to at least one condition selected from the group consi

Abstract: The invention relates to the platinum N-heterocycle derivatives of general formula (I) in which—R1 and/or R2 are, independently of one another, an aryl or aralkyl group, each optionally substituted, a linear or branched C1-C6 alkyl group, a monocyclic C3-C7 cycloalkyl group or a linear or branched C2-C6 alkenyl group, or else R? is a hydrogen atom and R is a group selected from the following groups: cycloalkyl or heterocycloalkyl, which is monocyclic or bicyclic and has from 3 to 8 carbon atoms, or benzyl, which is optionally substituted, or else R and R? form, together with NH, a C3-C8 monocyclic or bicyclic heterocycloalkyl, V is a nitrogen atom or a C—R4 radical, R3 and/or R4 are hydrogen or a phenyl group or R3 and R4 may also together form a C3-C6 alkylene radical or a C3-C6 heteroalkylene radical with one or more nitrogenous heteroatoms, it being possible for the carbon atoms of the heteroalkylene radical to be modified in the form of a carbonyl radical, and X is iodine, bromine, chlorine or a nitra

Abstract: Disclosed are nitric oxide delivery agents and methods of their use, more specifically to photoactive compounds, which are able to perform targeted delivery of nitric oxide in vitro and in vivo and are useful for medicinal applications including, but not limited, to blood pressure regulation and cancer treatment.

Abstract: The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders and obesity and methods of using pharmaceutical compositions of thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-?B dysregulation.

Abstract: The present invention relates to the use of ionic liquids as antimicrobial agents, and to the use of antimicrobial compositions comprising an ionic liquid, a film-enhancing composition and a viscosity controlling agent. The invention further relates to methods of disinfecting substrate surfaces, to substrates produced by such methods, and to novel ionic liquid compositions.

Abstract: The present invention is directed to a biocidal composition comprising a blend of one or more pyrithione compounds, and one or more pyrrole compounds of Formula I wherein said biocidal composition is copper free or low copper content.

Abstract: The present disclosure relates to methods of treating cancers that are responsive to antimetabolite or antimitotic anti-cancer agents. The methods involve the use of at least one anti-cancer agent selected from antimetabolite anti-cancer agents, antimitotic anti-cancer agents, and combinations thereof, and a superoxide dismutase mimetic to potentiate the therapeutic effect of the anti cancer agent(s).